Fu Wei 4

What Happened
Director Fu Wei was granted multiple derivative equity awards by NovaBridge Biosciences on 2026-06-29. The filing shows four awards totaling 3,910,680 American Depositary Shares (ADS) equivalents (725,140; 1,087,720; 1,087,720; and 1,010,100 ADS). All items are reported as awards/derivative acquisitions (code A) with a reported per-share price of $0.00 — these are grants/RSUs and/or option-type awards, not open‑market purchases or sales, so no cash changed hands at grant.

Key Details

• Transaction date reported: 2026-06-29; Form 4 filed 2026-06-30 (one day later).
• Total awards: 3,910,680 ADS (sum of four grants: 725,140; 1,087,720; 1,087,720; 1,010,100). Reported price: $0.00 (derivative awards).
• Shares owned after transaction: not disclosed in the excerpt of the filing.
• Footnotes / vesting conditions:
  • F1: All counts and prices are expressed in American Depositary Shares (ADS).
  • F6–F7: Some awards are restricted stock units (RSUs); each RSU = right to one ADS. RSUs vest in two equal annual installments on June 29, 2027 and June 29, 2028.
  • F2, F4, F5: Some awards are option-like and vest only if the 30‑trading‑day weighted average price of the issuer's ADS reaches specified thresholds ($8.00, $12.00, and $16.00). If the price condition is met, those options vest in eight equal quarterly installments thereafter.
  • F3: Ordinary shares may be represented by ADS; conversion ratio disclosed is 10 ADS = 23 Ordinary Shares.
• Filing timeliness: reported promptly (Form 4 filed the business day after the transaction); no late filing indicated.

Context
These are grants/derivative awards, not purchases or sales. For retail investors: RSUs and price‑conditioned options are contingent compensation — RSUs provide ADS only if/when they vest, and the options described will only vest if specified ADS price hurdles are met. Such awards are common for executive/director compensation and do not by themselves indicate immediate buying or selling in the market.